(NYSE: RDY) Dr Reddys Laboratories's forecast annual revenue growth rate of 3.69% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Dr Reddys Laboratories's revenue in 2025 is $3,785,730,898.On average, 3 Wall Street analysts forecast RDY's revenue for 2026 to be $3,273,973,942,202, with the lowest RDY revenue forecast at $3,261,310,247,583, and the highest RDY revenue forecast at $3,283,431,659,309. On average, 3 Wall Street analysts forecast RDY's revenue for 2027 to be $3,315,070,868,929, with the lowest RDY revenue forecast at $3,259,407,689,351, and the highest RDY revenue forecast at $3,380,712,465,761.
In 2028, RDY is forecast to generate $3,554,829,922,222 in revenue, with the lowest revenue forecast at $3,466,477,788,176 and the highest revenue forecast at $3,685,956,238,278.